- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT05211401
Rituksimabi potilailla, joilla on ST-korkeus sydäninfarkti (RITA-MI2)
Rituksimabi potilailla, joilla on ST-korkeus sydäninfarkti: Vaihe 2 Lumekontrolloitu satunnaistettu kliininen tutkimus: RITA-MI 2
The main objective is to compare the effect of a single injection of two doses of rituximab versus placebo on 6 months left ventricular systolic function, using CMR, in patients who have had an acute anterior STEMI. Following the sponsor's decision to stop enrolment in the 200 mg arm, the primary objective of the study is to evaluate the efficacy of a single 1000 mg dose of rituximab versus placebo.
The primary endpoint is the left ventricular ejection fraction (LVEF) by CMR at 6 months.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
RITA-MI 2 is an european phase IIb, multi-center, randomized, parallel, double-blind, placebo-controlled, clinical trial to assess the impact of B cell depletion with the CD20 mAb rituximab (1000mg) on left ventricular dysfunction and cardiac remodelling after acute MI.
Sample size :
372 patients, 1:1 ratio
Assessement:
Patients will be recruited immediately after admission for MI. The aim is to start the infusion of IMP within 3 hours of PPCI (defined as first balloon inflation).
Eligible patients will be offered to enter the study. In France, Spain and Czech Republic: If they accept, the investigator will collect informed written consent from the patient or from a person of trust/next of kin if the patient is unable to consent. While In Germany, UK and Netherlands, only the patient will be informed and will be able to give consent and no next-of-kin will be informed and have the possibility to give consent.
Once the inclusion is confirmed, a specific study blood sample will be taken for later assessment of cytokines and biomarkers related to immune responses, inflammation and cardiac remodelling. It will also be done at discharge and at 6 months.
According to usual practice the following blood exams will be done: Kidney function parameters (including serum creatinine, BUN, electrolytes, calcium and eGFR). It will also be done at day 5 (+ 2 days) and at 6 months.
NT-pro-BNP will be performed at admission and at 6 months. Blood leukocytes, platelets and hematologic/haemostatic parameters will also be measured at admission and at 6 months.
The randomization will be performed and the pharmacy will extemporaneously prepare (aseptically) 2 infusion bags per patient (cf. treatments below).
During the infusion, the patient will be carefully monitored with continuous cardiac telemetry:
- 12 lead ECG with QTc measurement will be performed pre-dosing and post-dosing at admission, discharge and at 6 months.
- Kidney functions. The patients will be carefully monitored by their treating physicians, as done in usual care, with a special attention to the occurrence of any adverse event related to treatment.
CMR will be done at 5 days (+ 2 days) to assess the left ventricular (LV) function, the infarct size and microvascular obstruction and at 6 months.
Study staff at the clinical sites will contact each patient at 30 days, 3 months and 12 months following randomization, by phone or during a hospital visit.
The patient participation will last after the 12-month visit.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Gabriel STEG
- Puhelinnumero: 01 40 25 86 68
- Sähköposti: gabriel.steg@aphp.fr
Tutki yhteystietojen varmuuskopiointi
- Nimi: Ziad MALLAT
- Puhelinnumero: 01 53 98 80 06
- Sähköposti: ziad.mallat@inserm.fr
Opiskelupaikat
-
-
-
Paris, Ranska, 75018
- Rekrytointi
- Cardiology department, Hôpital Bichat, AP-HP
-
Ottaa yhteyttä:
- Ziad MALLAT
- Puhelinnumero: 01 53 98 80 06
- Sähköposti: ziad.mallat@inserm.fr
-
Ottaa yhteyttä:
- Philippe Gabriel STEG
- Puhelinnumero: 01 40 25 86 68
- Sähköposti: gabriel.steg@aphp.fr
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Age ≥ 18 years with no upper limit (women must be either postmenopausal defined as being amenorrhoeic for greater than 2 years with an appropriate clinical profile, e.g. age appropriate (>55 years old), history of vasomotor symptoms) or having documented hysterectomy and/or bilateral oophorectomy) ;
- Clinical evidence at presentation of anterior ST-elevation myocardial infarction (STEMI) ) involving the proximal or mid left anterior descending (LAD) defined as symptoms suggestive of acute myocardial ischemia, an electrocardiogram showing ST-segment elevation ≥2 mm in ≥2 contiguous leads in V1 to V4 or a large inferior MI (right coronary artery (RCA), or left circumflex (LCx) coronary artery) with evidence of low-ejection fraction (LVEF<45%);
- Complete occlusion (i.e. TIMI flow 0-1) of proximal or mid left anterior descending (LAD) right coronary artery (RCA), or left circumflex (LCx) coronary artery on urgent angiography interpreted as the infarct-related artery (IRA);
- Onset of worse symptoms within 48 hours before primary PCI;
- Patients with neutrophils >1.5 x 109/L at the moment of admission
- Patients with platelet counts >75 x 109 /L at the moment of admission
- Plan to provide primary percutaneous angioplasty (PPCI) for the patient within 2 hours of ECG diagnosis; confirmed before enrollment;
- Ability to start infusion of rituximab within 3 hours of PPCI ; confirmed before enrollment;
- Written informed consent.
Exclusion Criteria:
Exclusion Criteria :
- History of previous MI without documented preserved left ventricular ejection fraction (LVEF >50%) prior to the current admission will be an exclusion criterion;
- Presentation with cardiac arrest;
- Cardiogenic shock (defined as systolic blood pressure <90 mmHg for >30minutes, or necessitating vasopressors to achieve a blood pressure ≥90 mmHg);
- Cardiac electrical instability (defined as complete heart block needing temporary pacing or any tachyarrhythmia needing cardioversion);
- Patients with Killip class III heart failure;
- History of severe chronic renal failure (define as stage 4 (GFR = 15-29 mL/min) or worse);
- History of hepatitis B, HIV or tuberculosis;
- Patient positive for point of care bedside test of Ag HBs;
- Severe, progressive infections documented;
- Active COVID-19 infection or COVID-19 infection within 3 months;
- Patient with documented severe immune deficiency;
- Presence, or history in ≤ five years, of an ongoing cancer, (except in situ cancer of the cervix or basal cell carcinoma);
- QTcF> 450 msecs in males, > 470msecs in females;
- Any oral or intravenous immunosuppressive treatment, immune modulatory monoclonal antibodies or immunodepleting therapy at any time (inhalers and topical creams with corticosteroids are permitted);
- Previous history of major organ transplant including renal transplant;
- Known hypersensitivity to the active substance of rituximab or to proteins of murine origin, or to any of the other excipients;
- Any contraindications to any of the rituximab premedication drugs;
- Contraindications to injectable Polaramine:
Risk of closed-angle glaucoma, Risk of urinary retention linked to urethro-prostatic disorders;
- Expected need for vaccination with a live attenuated vaccine during the study, including incomplete vaccination courses (in case, life, attenuated vaccine must be administered at least 30 days before inclusion in study);
- Absence of a complete COVID-19 vaccination scheme (including recovery from documented COVID infection) as approved at the time of enrollment in the country where the patient is recruited;
- Any obvious contraindications for MRI or conditions which will impede image acquisition for example:
Severe claustrophobia
Non-MRI compatible permanent pacemaker
Patients who have a metallic foreign body (metal silver) in their eye, or who have an aneurysm clip in their brain
Patients who have had metallic devices placed in their back
Known hypersensitivity to imaging products (gadoteric acid, meglumin or any drug containing gadolinium)
- Known hepatic failure;
- Previous history of progressive multifocal leukoencephalopathy;
- Inclusion in other interventional drug study within the previous 3 months;
- Inability to comply with study procedures;
- Patients under guardianship or curatorship.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Active arm 1000 mg
Active arm 1000 mg: 1 bag containing 1000 mg of rituximab* in 500 ml of NaCl 0.9% * Mabthera® and all registered biosimilars are likely to be used in this trial. |
Active arm 1000 mg: 1 bag containing 1000 mg of rituximab* in 500 ml of NaCl 0.9% * Mabthera® and all registered biosimilars are likely to be used in this trial |
|
Placebo Comparator: Placebo arm
1 bag of 500 ml of NaCl 0.9% |
Placebo arm: 1 bag of 500 ml of NaCl 0.9% |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Left ventricular ejection fraction (LVEF) by CMR at 6 months.
Aikaikkuna: 6 months
|
To compare the effect of a single injection of two doses of rituximab versus placebo on 6 months left ventricular systolic function, using CMR, in patients who have had an acute anterior STEMI. |
6 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Infarct size by CMR
Aikaikkuna: At day 5 (+/-2) and at 6 months
|
To compare the effects of rituximab versus placebo on infarct size by CMR at day 5 (+/-2) and at 6 months. |
At day 5 (+/-2) and at 6 months
|
|
Oedema extension by CMR
Aikaikkuna: At day 5 (+/-2)
|
To compare the effects of rituximab versus placebo on oedema extension by CMR at day 5 (+/-2) . |
At day 5 (+/-2)
|
|
T2 relaxation time at ischemic region by CMR
Aikaikkuna: At day 5 (+/-2)
|
To compare the effects of rituximab versus placebo on T2 relaxation time at ischemic region by CMR (using T2 mapping) at day 5 (+/-2). |
At day 5 (+/-2)
|
|
Microvascular obstruction by CMR
Aikaikkuna: At day 5 (+/-2)
|
To compare the effects of rituximab versus placebo on microvascular obstruction by CMR (hypointense areas within LGE) at day 5 (+2/-) . |
At day 5 (+/-2)
|
|
NT-pro-BNP
Aikaikkuna: At 6 months
|
To compare the effects of rituximab versus placebo on NT-pro-BNP at 6 months. |
At 6 months
|
|
Adverse event related to treatment
Aikaikkuna: Until 12 months
|
To compare the effects of rituximab versus placebo on any adverse event related to treatment . |
Until 12 months
|
Yhteistyökumppanit ja tutkijat
Yhteistyökumppanit
Tutkijat
- Päätutkija: Gabriel STEG, Assistance Publique - Hôpitaux de Paris
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- APHP210015
- 2021-003340-24 (EudraCT-numero)
- 2022-501893-21-00 (Muu tunniste: EU Clinical Trial number)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .